Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian CancerNelofer Syed, Tim Crook, Eleftheria Hatzimichael et al.|Cancer Research|2011Cited by 60
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in cancerHelen M. Coley, Nelofer Syed, Eleftheria Hatzimichael et al.|Oncotarget|2012Cited by 33
Supplementary Figure 3 from Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian CancerNelofer Syed, Tim Crook, Helen M. Coley et al.|Unknown|2023Cited by 0
Supplementary Table 1 from Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian CancerNelofer Syed, Tim Crook, Helen M. Coley et al.|Unknown|2023Cited by 0
Supplementary Figure 3 from Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian CancerNelofer Syed, Tim Crook, Peter Schmid et al.|Unknown|2023Cited by 0